Pharmaceuticals

We assist our pharmaceutical clients in identifying and protecting IP assets, performing IP due diligence of acquisition targets, advancing and managing new discoveries, developing legal infrastructure, and expanding and protecting US and other commercial interests.

Our attorneys are involved in strategic counseling and litigation activities assembling and asserting patent rights in Hatch-Waxman litigation.

In addition, we work closely with PBMs on multiple matters including significant ERISA issues.

Select News & Events

• ERISA Attorneys Win Twice for Caremark
• After Ariad v. Lilly: Implications and Best Practices

Publications

• Section 337 Update - April Activities Affecting the US International Trade Commission
  April 27, 2010
• The Curse Of The Traveling Shorts - Corporate Officer Narrowly Escapes Personal Liability, But An (Unnecessary?) Eight-Year Battle Lingers On
  February 12, 2010
• Duty Suspension Requests Due by the End of the Month
  October 13, 2009
• Ruling Removes FDA Safety Net
  May 2009, Global Reinsurance

More Publications »